Skip to content
DataLookout
Menu

NCT07629583

To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 1 → 11 locations
    • Start date changed from estimate of Oct 31, 2026 to Nov 2, 2026
  2. Notable Eligibility criteria expanded, about 20 words
    • Study sites: 1 to 2
  3. Notable Recruitment opened
    • Start date: Jul 31, 2026 to Oct 31, 2026
    • Study sites: 0 to 1
    v3
  4. Study Status, Contacts/Locations, Referencesv2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Participants with Adverse Events (AEs)
Timeframe: Up to approximately 52 weeks

Secondary (7)

Serum Concentration of Cevostamab
Area Under the Concentration-Time Curve (AUC) of Cevostamab
Maximum Observed Serum Concentration (Cmax) of Cevostamab
Minimum Observed Serum Concentration (Cmin) of Cevostamab
Clearance (CL) of Cevostamab
Show 2 moreShow less
Volume of Distribution at Steady State (Vdss) of Cevostamab
Change from Baseline in the Presence Anti-Drug Antibodies (ADAs)

Arms and interventions

Dose Escalation and ExpansionExperimental

The study consists of a dose-escalation stage followed by an expansion stage. Participants in both stages will receive Cevostamab in a step-up dosing regimen, followed by a target dose.

Drugs: Cevostamab, Tocilizumab

Sites

11 sites in 6 countries

Brazil 4, China 3, Australia 1, France 1, Italy 1, Spain 1